Hartmut Dohner

Albert Einstein Allee 23
Ulm, BW 89081, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 364 publications

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

Journal: BMC cancer

Published: June 16, 2026

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Journal: Haematologica

Published: March 20, 2026

Impact of post-transplant cyclophosphamide and anti-thymocyte globulin on immune reconstitution in MUD allo-HCT.

Impact of post-transplant cyclophosphamide and anti-thymocyte globulin on immune reconstitution in MUD allo-HCT.

Journal: Frontiers in immunology

Published: February 28, 2026

Machine learning provides individualized prediction of outcomes after first complete remission without allo-HSCT consolidation in adult acute myeloid leukemia-A HARMONY study.

Machine learning provides individualized prediction of outcomes after first complete remission without allo-HSCT consolidation in adult acute myeloid leukemia-A HARMONY study.

Journal: HemaSphere

Published: February 23, 2026

Rapid and Reproducible Karyotyping with Long Read Sequencing in AML Patients.

Rapid and Reproducible Karyotyping with Long Read Sequencing in AML Patients.

Journal: Blood advances

Published: February 02, 2026

Letermovir does not affect long-term polyclonal immune reconstitution after allogeneic hematopoietic stem cell transplantation with ATG-based GvHD prophylaxis.

Letermovir does not affect long-term polyclonal immune reconstitution after allogeneic hematopoietic stem cell transplantation with ATG-based GvHD prophylaxis.

Journal: Frontiers in immunology

Published: January 18, 2026

Tree-based exploratory identification of predictive biomarkers in non-randomized data.

Tree-based exploratory identification of predictive biomarkers in non-randomized data.

Journal: BMC medical research methodology

Published: December 24, 2025

Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML.

Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML.

Journal: Future oncology (London, England)

Published: November 19, 2025

ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed IDH1 mutant acute myeloid leukemia.

ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed IDH1 mutant acute myeloid leukemia.

Journal: Future oncology (London, England)

Published: November 16, 2025

Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.

Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.

Journal: Leukemia

Published: October 20, 2025

APL-like subset within NPM1-mutated AML: A distinct immunophenotype correlating with early vascular complications.

APL-like subset within NPM1-mutated AML: A distinct immunophenotype correlating with early vascular complications.

Journal: HemaSphere

Published: September 15, 2025

Tailoring intensive and less-intensive treatment in acute myeloid leukemia.

Tailoring intensive and less-intensive treatment in acute myeloid leukemia.

Journal: Seminars in hematology

Published: August 25, 2025

Showing 1-12 of 364

Last Updated: 09/26/2026